Search for European Projects

34 European Projects Found

Searched on 125080 European Projects

 FINISHED 
..., and the University of Toronto’s SGC laboratory (UTOR-SGC, will not receive IMI funds), led by Cheryl Arrowsmith, and chemical biology teams in Bayer (Bayer), Janssen (JPNV), Novartis (NOV) and Pfizer (Pfizer). The Clinical Immunology Core will generate high quality assays from patient-derived cells and tissues in selected inflammatory diseases, and test effects of the chemical and antibody probe ...
Read Project

 10

 FINISHED 

European Prevention of Alzheimer’s Dementia Consortium (EPAD)

Start date: Jan 1, 2015, End date: Dec 31, 2019,

Background:The secondary prevention of Alzheimer’s dementia (AD) is achievable if we can identify individuals at risk of disease progression defined by biomarker evidence of AD pathology and no or only minimal clinical symptoms and engage them in a standing adaptive clinical trial, of the highest quality, testing multiple interventions. To achieve this, EPAD will also provide the analytical infras ...
Read Project

 40

 FINISHED 

Intelligent Assessment of Pharmaceutical in the Environment (IPIE)

Start date: Jan 1, 2015, End date: Dec 31, 2018,

Active pharmaceutical ingredients (APIs) can be released to the natural environment during the manufacturing process, following use by patients or when unused medicines are disposed of. As APIs are biologically active compounds concerns have been raised about the potential effects of APIs in the environment on human and environmental health. Over the past 15 years, a substantial amount of work has ...
Read Project

 29

 FINISHED 
Aim: The ADVANCE vision is focused on Timely and Best Evidence on Vaccine Effects. Our mission is to establish a best practice framework to rapidly provide robust data on vaccine benefits and risks to support accelerated decision-making.Approach: To achieve this vision through a public-private partnership, ADVANCE partners 1. establish common grounds and rules for collaboration between public and ...
Read Project

 30

 FINISHED 

European Medical Information Framework (EMIF)

Start date: Jan 1, 2013, End date: Dec 31, 2017,

In response to the need to tackle increasingly complex medical research questions, a growing amount of human health data is being collected, either in routine Electronic Healthcare Record (EHR) databases, through research-driven cohort studies, in biobanks or related efforts. However, data sources are typically fragmented and contain information gaps which prevent their full exploitation. EMIF aim ...
Read Project

 64

 FINISHED 
The QuIC-ConCePT consortium has 2 objectives: 1.(90% of resource, WP2-5) to qualify 3 specific imaging biomarkers (IBs) of tumour cell proliferation, apoptosis, and necrosis, to allow drug developers to demonstrate reliably modulation of these pathologic processes in tumours in patients in realistic trials. Our vision for January 2016 is that drug developers can incorporate these IBs for decision- ...
Read Project

 26

 FINISHED 
The CRYDIS exchange programme will establish and support international and inter-sectoral transfer of knowledge and expertise in pharmaceutical and instrument science between several EU research institutes and industrial companies. It will also enhance understanding of the value of inter-sectoral exchange mechanisms for taking research to market.CRYDIS undertakes innovative, collaborative research ...
Read Project

 5

 FINISHED 
Most biopharmaceuticals (BP) currently on the market are recombinant proteins which are parenterally administered. These would benefit from more patient-friendly routes of administration. Moreover, new classes of BP (e.g. siRNA, miRNA, DARPins) with specificity for intracellular targets hold promise but await the advent of efficient delivery systems before their potential can be realised into ther ...
Read Project

 22

 FINISHED 
Since its inception the IMI has funded over 30 public-private partnership projects. Many of these projects are centered upon data intensive translational research and are employing integrative analysis approaches to achieve their goals. Although a common KM platform for IMI projects was envisioned in the original IMI Strategic Research Agenda it has not yet been implemented. The lack of a common p ...
Read Project

 17

 FINISHED 

DRIVING RE-INVESTMENT IN R&D AND RESPONSIBLE ANTIBIOTIC USE (DRIVE-AB)

Start date: Oct 1, 2014, End date: Sep 30, 2017,

Antimicrobial resistance (AMR) is widespread. Its global human and economic burden is tremendous and increasing annually. Yet today only a few pharmaceutical companies retain active antibacterial drug discovery programmes. While the elaboration of antibiotics with novel mechanisms of action is scientifically complex, the chief challenge is diminishing incentives. Pre-market regulatory requirements ...
Read Project

 27

 FINISHED 
StemBANCC, comprising internationally renowned investigators, is ideally positioned to deliver a unique European biorepository and drug discovery pipeline based upon human induced pluripotent stem cells (hiPSC). This unrivalled opportunity will address the pressing therapeutic need in neurodegeneration, neurodysfunction and diabetes. We have immediate access to richly phenotyped subjects with a we ...
Read Project

 38

 FINISHED 

Oral biopharmaceutics tools (ORBITO)

Start date: Oct 1, 2012, End date: Sep 30, 2017,

The OrBiTo project will deliver novel methods and a framework for rational application of predictive biopharmaceutics tools for oral drug delivery. This will be achieved through novel propsective studies to define new methodlogies which will be validated using historical datasets from EFPIA partners. A combination of high quality in vitro or in silico characterizations of API and formulations will ...
Read Project

 28

 FINISHED 
Despite dramatic advances in molecular and imaging technologies, there are currently no effective pharmacological treatments for the core symptoms of autism spectrum disorder (ASD). Major obstructions to this include a lack of aetiologically-driven or pathophysiologically-accurate animal models; an absence of tests that indicate efficacy; and reliance of clinical trials on DSM/ICD10 categories wh ...
Read Project

 29

 FINISHED 

BeTheCuRE (BTCURE)

Start date: Apr 1, 2011, End date: Mar 31, 2017,

BTCure is based on the recognition that RA is a heterogeneous disease where a major subset involves adaptive immunity, and that animal models have to develop the line with the different subsets of the human diseases in order to be optimally used for drug discovery and drug evaluation. Our aim is to develop an understanding of the early process in human arthritis subsets and the animal models that ...
Read Project

 41

 FINISHED 
The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique panel of experts from different disciplines. ABIRISK will involve many of the European leaders in rheumatology, gastroenterology, hemophilia and multiple sclerosis, caring for ~30,000 patients treated with biopharmaceuticals, with ~10,000 additional patients recru ...
Read Project

 39

 FINISHED 

European Patients' Academy on Therapeutic Innovation (EUPATI)

Start date: Feb 1, 2012, End date: Jan 31, 2017,

"The proposed project ""European Patients' Academy on Therapeutic Innovation"" (EUPATI) contributes to IMI’s goal of raising patients’ awareness and participation in pharmaceutical R&D. This patient-led academy will provide scientifically reliable, objective, comprehensive information to patients on pharmaceutical R&D. It will increase the capacity of well-informed patients to be effective advocat ...
Read Project

 33

 FINISHED 

European Bank for induced pluripotent Stem Cells (EBISC)

Start date: Jan 1, 2014, End date: Dec 31, 2016,

...s and, being representative of all stakeholders from tissue donors to clinical and academic iPSC researchers and industrial users, to respond appropriately to advances in science and society. Led by Pfizer Ltd and managed by Roslin Cells, the Consortium comprises 8 active participant iPSC Centres with clinical and patient networks, a global leader in industrial iPSC supply, international experts ...
Read Project

 30

 FINISHED 
We propose here an exhaustive analysis of the genome, exome, methylome and transcriptome of primary tumours and metastases from patients with colon carcinoma, based on a combination of deep sequencing and chip based techniques. Dependent on their availability, we shall also perform analyses of tumor stem cells, circulating tumor cells, free tumor DNA in serum and xenografts derived from the same p ...
Read Project

 22

 FINISHED 
The eTOX consortium proposes to develop innovative methodological strategies and novel software tools to better predict the toxicological profiles of new molecular entities in early stages of the drug development pipeline. This will be achieved by coordinating the efforts of specialists from academia and SMEs in the wide scope of disciplines that are required to move towards a more reliable modell ...
Read Project

 30

 FINISHED 
Background:In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has been identified by EUFEPS. The IMI (‘Strategic Research Agenda’), the FDA and the EMEA have also characterised this fact as a crucial gap in the education and training of scientists evaluating the safety of drug candidates and new medicines. Scope and objecti ...
Read Project

 34

 FINISHED 
CHEM21 is a project that will develop a broad based portfolio of sustainable technologies for green chemical intermediate manufacture aimed at the pharmaceutical industry. Initially working with the EFPIA members the collaborators of CHEM21 will analyse a number of projects that are in development to decide which the priorities are for technology development. This analysis will also be used to upd ...
Read Project

 19

 FINISHED 

European Medicines Research Training Network (EMTRAIN)

Start date: Oct 1, 2009, End date: Sep 30, 2016,

EMTRAIN is an essential element for the success of the IMI Education & Training (E&T) Call Topics in Europe (current and future). It will establish a pan-European platform of excellence for education and training covering the whole life-cycle of medicines from basic research through clinical development to pharmaco-vigilance. It will underpin the successful delivery of the current and future IMI-f ...
Read Project

 32

 FINISHED 

Drug Disease Model Resources (DDMORE)

Start date: Mar 1, 2011, End date: Aug 31, 2016,

Model based-drug development (MBDD) is accepted as a vital approach in understanding patient risk/benefit and attrition. At the core of MBDD lies Modelling and Simulation (M&S), a technology providing the basis for informed, quantitative decision-making.M&S facilitates the continuous integration of available information related to a drug or disease into constantly-evolving mathematical models capa ...
Read Project

 28

 FINISHED 
Physical activity (PA) is essential in maintaining optimal health in chronic diseases, including COPD.More physically active patients have less hospital admissions and better survival. Validated physicalactivity monitors have become available in recent years, and together with patient report of symptomsand distress of physical (in)activity, this may form a potent new Patient Reported Outcome (PRO) ...
Read Project

 20

 FINISHED 

The Open Pharmacological Concepts Triple Store (OPEN PHACTS)

Start date: Mar 1, 2011, End date: Feb 29, 2016,

Drug discovery is data-hungry and all major pharmaceutical companies maintain extensive in-house instances of public data alongside internal. Analysis and hypothesis generation for drug-discovery projects requires assembly, overlay and comparison of data from many sources, requiring shared identifiers and common semantics. Expression profiles need to be overlaid with gene or pathway identifiers an ...
Read Project

 32

 FINISHED 
Diabetes mellitus is a lifelong, incapacitating disease affecting multiple organs. Worldwide prevalence figures estimate that there will be 246 million diabetic patients in 2007 and 380 million in 2025. Presently, diabetes can neither be prevented nor cured and the disease is associated with devastating chronic complications including coronary heart disease and stroke (macrovascular disease) as we ...
Read Project

 27

 FINISHED 

Understanding chronic pain and improving its treatment (EUROPAIN)

Start date: Oct 1, 2009, End date: Sep 30, 2015,

We will establish an international team of leading researchers and clinicians (EuroPain) to undertake multidisciplinary translational research which will: 1) increase the understanding of chronic pain mechanisms; 2)facilitate the development of novel analgesic drugs; and 3) improve the treatment of chronic pain patients.Nineteen researchers drawn from the London Pain Consortium, the Danish Pain Re ...
Read Project

 29

 FINISHED 
RationaleThe inability of pre-clinical studies to predict clinical efficacy is a major bottleneck in drug development. In severe asthma this bottleneck results from: a lack of useful and validated biomarkers, underperforming pre-clinical models, inadequate and incomplete sub-phenotyping, and insufficient disease understanding.HypothesisThe use of biomarker profiles comprised of various types of hi ...
Read Project

 42

 FINISHED 

SAFER AND FASTER EVIDENCE-BASED TRANSLATION (SAFE-T)

Start date: Jun 15, 2009, End date: Jun 14, 2015,

The public-private consortium composed of complementary SMEs, academic and clinical centers of excellence and EMEA as partner proposes SAFE-T (Safer And Easter Evidence-based Iranslation) project for the establishment of a biomarker (BM) qualification process and its validation in clinical biomarker studies designed for the translation, performance testing and eventual regulatory qualifIcatIon of ...
Read Project

 26

 FINISHED 
Recent pharmacovigilance (PV) issues have led to questions regarding the ability of the current PV system to meet the global needs. Controversies around the assessment of spontaneous reports and conflicting results from pharmacoepidemiology studies may lead to delay in, or inappropriate, regulatory decisions. The PROTECT consortium, consisting of 20 core partners lead by the European Medicines Age ...
Read Project

 36

 FINISHED 

Vaccines against helminth infections (PARAVAC)

Start date: Apr 1, 2011, End date: Mar 31, 2015,

Livestock production efficiency is impaired by helminth infection which is ubiquitous in cattle, sheep and goats world-wide. It causes severely debilitating gastro-intestinal, respiratory and hepatic disorders, dependent on the infecting species. The treatment and prevention of helminth parasitism in livestock continues to rely almost exclusively on the use of anthelmintic drugs, an approach thre ...
Read Project

 26

 FINISHED 
Despite dramatic advances in molecular and imaging technologies and nearly 1 5,000 articles on schizophrenia and depression (S&D) there are few novel treatments. We think this is because of three major “bottle-necks”: a lack of etiologically-driven or pathophysiologically-accurate animal models; a lack of tests that provide indication of efficacy in healthy volunteers; and the reliance of clinical ...
Read Project

 20

 FINISHED 

Pharmaceutical Medicine Training Programme (PHARMATRAIN)

Start date: May 1, 2009, End date: Apr 30, 2014,

"The proposed Pharmaceutical Medicine Training Programme provides a comprehensive solution for the complex needs of integrated drug development for all professionals involved, incl. physicians, pharmaceutical scientists,biologists, biometricians, health economists, and safety and regulatory scientists from universities, regulatory agencies, large, middle-sized and small pharmaceutical enterprises, ...
Read Project

 52

 FINISHED 
Incontinence affects almost 66 million people in the European Union. The Over Active Bladder (OAB) symptom complex is one of the major causes for incontinence, with a large number of affected persons and immense associated health care costs. The causes for the over active bladder contractions, underlying the urinary urgency of OAB are unknown, and current treatments are only partially effective. T ...
Read Project

 10